DİDEM PEKMEZCİ, Ümit ÖZCAN, YÜCEL MERAL, Duygu DALĞIN, Gulay CIFTCI

Evaluation of Feline-Specific Serum Sulphated Glycosaminoglycan and Dermatan Sulphate Levels in Cats with Non-Obstructive Lower Urinary Tract Dysfunction

Lower urinary tract dysfunction (LUTD) is a commonly seen problem in cats. This chronic condition with no specific underlying cause remainsa challenge for achieving eff ective treatment. Glycosaminoglycans (GAGs) are linear polysaccharides possessing characteristic repeateddisaccharide sequences, thought to be involved in the pathogenesis of feline LUTD. The aim of the present study is to evaluate feline-specificserum sulphated glycosaminoglycan (S-GAG) and serum dermatan sulphate (DS) levels in cats with non-obstructive LUTD versus healthycontrols. Eighteen client-owned cats suff ering non-obstructive LUTD and 16 client-owned healthy cats were enrolled in this case-controlstudy. Pre-treatment serum samples from cats in both the study (non-obstructive LUTD cats) and control (healthy cats) groups were analysedwith “Quantitative Sandwich ELISA method” using feline-specific S-GAG and DS kits. The mean serum S-GAG and DS levels of the study groupwere measured against the control group. Measurements for study males were compared to the control males, and the neutered cats inthe study group were compared to the intact ones in control group. Cats in study group had lower serum S-GAG concentrations (3.52±0.26ng/mL) than the control ones (3.93±0.27 ng/mL). Cats in study group had higher serum DS levels (27.20±6.62 ng/mL) than control cats(16.79±5.21 ng/mL). This study reports serum S-GAG and DS data in cats with non-obstructed LUTD and in healthy cats for the first time.

Tıkanıklık Olmayan Aşağı Üriner Sistem Disfonksiyonu Olan Kedilerde Felin Spesifik Serum Sulfürlü Glikozaminoglikan ve Dermatan Sülfat Seviyelerinin Değerlendirilmesi

Alt üriner sistem disfonksiyonu (AÜSD) kedilerde yaygın olarak görülen bir sorundur. Altta yatan belirli bir nedeni olmayan bu kronik durum, etkili tedaviye ulaşmak için bir zorluk olmaya devam etmektedir. Glikozaminoglikanlar (GAG’lar), AÜSD’nun patogenezinde rol oynadığı düşünülen karakteristik tekrarlanan disakkarit sekanslarına sahip doğrusal polisakkaritlerdir. Bu çalışmanın amacını, tıkanıklık olmayan AÜSD gösteren kedilerde, kedilere özgü serum sülfatlanmış glikozaminoglikan (S-GAG) ve dermatan sülfat (DS) düzeylerinin sağlıklı kontrollere göre karşılaştırılması oluşturmuştur. Bu vaka kontrol çalışmasında, tıkanıklık olmayan AÜSD’dan mustarip, sahipli on sekiz kedi ile sahipli 16 adet sağlıklı kedi yer almıştır. Hem çalışma (tıkanıklık olmayan AÜSD kediler) hem de kontrol (sağlıklı kediler) grubundaki kedilerden alınan tedavi öncesi serum örnekleri, kedilere özgü S-GAG ve DS kitleri kullanılarak “Kantitatif Sandviç ELISA yöntemi” ile analiz edilmiştir. Çalışma ve kontrol gruplarına ait tüm kediler ile, çalışma ve kontrol grubundaki erkek kediler ve her iki gruptaki sterilize edilmiş kedilerin ortalama serum S-GAG ve DS seviyeleri karşılaştırılmıştır. Çalışma grubunun serum S-GAG konsantrasyonları (3.52±0.26 ng/mL) kontrol grubuna kıyasla daha düşük (3.93±0.27 ng/mL) bulunmuştur. Tersine çalışma grubu serum DS seviyeleri ise (27.20±6.62 ng/mL) kontrol grubuna (16.79±5.21 ng/ mL) oranla yüksek bulunmuştur. Bu çalışma, tıkanma olmayan AÜSD’si kedilerde ve sağlıklı kedilerde ilk kez serum S-GAG ve DS verilerini bildirmektedir.

PDF

___

1. Westropp JL, Delgado M, Buffington CAT: Chronic lower urinary tract signs in cats: Current understanding of pathophysiology and management. Vet Clin North Am Small Anim Pract, 49 (2): 187-209, 2019. DOI: 10.1016/j.cvsm.2018.11.001

2. Wallius BM, Tidholm AE: Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: A double-blind, randomised, placebo-controlled trial. J Feline Med Surg, 11 (6): 409-412, 2009. DOI: 10.1016/j.jfms.2008.09.003

3. Labato MA, Acierno MJ: Urology, An Issue of Veterinary Clinics of North America: Small Animal Practice. Volume 49-2, 125-324, Elsevier, USA, 2019.

4. Nivy R, Segev G, Rimer D, Bruchim Y, Aroch I, Mazaki-Tovi M: A prospective randomized study of efficacy of 2 treatment protocols in preventing recurrence of clinical signs in 51 male cats with obstructive idiopathic cystitis. J Vet Intern Med, 33 (5): 2117-2123, 2019. DOI: 10.1111/ jvim.15594

5. Buffington CAT, Chew DJ, Woodworth BE: Feline interstitial cystitis. J Am Vet Med Assoc, 215 (5): 682-687, 1999.

6. Naarden B, Corbee RJ: The effect of a therapeutic urinary stress diet on the short‐term recurrence of feline idiopathic cystitis. Vet Med Sci, 6 (1): 32-38, 2020. DOI: 10.1002/vms3.197

7. Bradley AM, Lappin MR: Intravesical glycosaminoglycans for obstructive feline idiopathic cystitis: A pilot study. J Feline Med Surg, 16 (6): 504-506, 2014. DOI: 10.1177/1098612X13510918

8. Meyer HP, Bečvářová I: Effects of a urinary food supplemented with milk protein hydrolysate and L-tryptophan on feline idiopathic cystitis – Results of a case series in 10 cats. Intern J Appl Res Vet Med, 14 (1): 59-65, 2016.

9. Delille M, Frohlich L, Muller RS, Hartman K, Dorsch R: Efficacy of intravesical pentosan polysulfate sodium in cats with obstructive feline idiopathic cystitis. J Feline Med Surg, 18 (6): 492-500, 2016. DOI: 10.1177/1098612X15588934

10. Buffington CAT, Blaisdell JL, Binns SP, Woodworth BE: Decreased urine glycosaminoglycan excretion in cats with interstitial cystitis. J Urol, 155 (5): 1801-1804, 1996. DOI: 10.1016/S0022-5347(01)66201-3

11. Lavelle JP, Meyers SA, Ruiz WG, Buffington CAT, Zeidel ML, Apodaca G: Urothelial pathophysiological changes in feline interstitial cystitis: A human model. Am J Physiol Renal Physiol, 278 (4): F540-F553, 2000. DOI: 10.1152/ajprenal.2000.278.4.F540

12. Sparkes A: Understanding feline idiopathic cystitis. In Practice, 40 (3): 95-101, 2018. DOI: 10.1136/inp.k435

13. Berger RE, Miller JE, Rothman I, Rothman I, Krieger JN, Muller CH: Bladder petechiae after cystoscopy and hydrodistension in men diagnosed with prostate pain. J Urol, 159 (1): 83-85, 1998. DOI: 10.1016/ S0022-5347(01)64018-7

14. Morales A, Emerson L, Nickel JC, Lundie M: Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol, 156 (1): 45-48, 1996. DOI: 10.1016/S0022-5347(01)65933-0

15. Parsons CL: Epithelial coating techniques in the treatment of interstitial cystitis. Urology, 49 (5): 100-104, 1997. DOI: 10.1016/S0090- 4295(97)00180-5

16. Shupp-Byrne DE, Sedor JF, Soroush M, McCue PA, Mulholland SG: Interaction of bladder glycoprotein GP51 with uropathogenic bacteria. J Urol, 165 (4): 1342-1346, 2001. DOI: 10.1016/S0022-5347(01)69896-3

17. Dissayabutra T, Kalpongnukul N, Chindaphan K, Srisa-Art M, Ungjaroenwathana W, Kaewwongse M, Lampenkhae K, Tosukhowong P: Urinary sulfated glycosaminoglycan insufficiency and chondroitin sulfate supplement in urolithiasis. PloS One, 14 (3): e0213180, 2019. DOI: 10.1371/journal.pone.0213180

18. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM: The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med, 18, 1217– 1223, 2012. DOI: 10.1038/nm.2843

19. Lucon M, Martins JR, Leite KRM, Soler R, Nader HB, Srougi M, Bruschini H: Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis. Int Braz J Urol, 40 (1): 72-79, 2014. DOI: 10.1590/S1677-5538.IBJU.2014.01.11

20. Pereira DA, Aguiar JAK, Hagiwara MK, Michelacci YM: Changes in cat urinary glycosaminoglycans with age and in feline urologic syndrome. Biochim Biophys Acta Gen Subj, 1672 (1): 1-11, 2004. DOI: 10.1016/j. bbagen.2004.02.002

21. Laurent TC, Laurent UBG, Fraser JER: Serum hyaluronan as a disease marker. Ann Med, 28 (3): 241-253, 1996. DOI: 10.3109/07853899609033126

22. Papaioannou EG, Magkou C, Kostakis A, Staikou C, Mitsoula P, Kyriakides S, Sitaras NM: Changes in total serum glycosaminoglycan levels in patients undergoing renal transplantation: Preliminary data. Surg Today, 34, 668-672, 2004. DOI: 10.1007/s00595-004-2795-4

23. Trowbridge JM, Gallo RL: Dermatan sulfate: New functions from an old glycosaminoglycan. Glycobiology, 12 (9): 117R-125R, 2002. DOI: 10.1093/glycob/cwf066

24. Gunn-Moore DA, Shenoy CM: Oral glucosamine and the management of feline idiopathic cystitis. J Feline Med Surg, 6 (4): 219-225, 2004. DOI: 10.1016/j.jfms.2003.09.007

25. Panchaphanpong J, Asawakarn T, Pusoonthornthum R: Effects of oral administration of N- acetyl-D-glucosamine on plasma and urine concentrations of glycosaminoglycans in cats with idiopathic cystitis. Am J Vet Res, 72 (6): 843-850, 2011. DOI: 10.2460/ajvr.72.6.843

26. Veir JK, Webb CB, Lappin MR: Systemic effects of a commercial preparation of chondroitin sulfate, hyaluronic acid and N acetyl-Dglucosamine when administered parenterally to healthy cats. Intern J Appl Res Vet Med, 11 (2): 91-95, 2013.

27. Wilkinson DR, Erickson DR: Urinary and serologic markers for interstitial cystitis: An update. Curr Urol Rep, 7 (5): 414-422, 2006.

28. Griffin S: Feline abdominal ultrasonography: what’s normal? what’s abnormal? The kidneys and perinephric space. J Feline Med Surg, 22 (5): 409-427, 2020. DOI: 10.1177/1098612X20917598

29. Lundberg JON, Carlsson S, Engstrand L, Morcos E, Wiklund NP, Weitzberg E: Urinary nitrite: More than a marker of infection. Urology, 50 (2): 189-191, 1997. DOI: 10.1016/S0090-4295(97)00257-4

30. Norsworthy GD, Restine LM, Romeo A: Normal Laboratory Values. In, Norsworthy GD (Ed): The Feline Patient. 5th ed.,John Wiley & Sons, 2018.

31. Buffington CAT, Chew DJ, DiBartola SP: Interstitial cystitis in cats. Vet Clin North Am Small Anim Pract, 26 (2): 317-326, 1996. DOI: 10.1016/ S0195-5616(96)50212-3

32. Parys M, Yuzbasiyan-Gurkan V, Kruger JM: Serum cytokine profiling in cats with acute idiopathic cystitis. J Vet Intern Med, 32 (1): 274-279, 2018. DOI: 10.1111/jvim.15032

33. Brooks B, Briggs DM, Eastmond NC, Fernig DG, Coleman JW: Presentation of IFN-gamma to nitric oxide-producing cells: A novel function for mast cells. J Immunol, 164 (2): 573-579, 2000. DOI: 10.4049/ jimmunol.164.2.573